et140203 t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 12, 2020 (NCT04502082)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-fetoproteinImmunity, passive
AFP immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04634357 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Aeon Therapeutics (Shanghai) Co., Ltd. |
| NCT04502082 | Phase 1/Phase 2 (Phase 2) | Nov 12, 2020 | Aeon Therapeutics (Shanghai) Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aeon Therapeutics (Shanghai) Co., Ltd. | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1